Launch apps instantly. Claim $200 credits on DigitalOcean for free!
Written by Sam » Updated on: January 16th, 2025
Europe Biosimilar Market 2025-2033
According to IMARC Group's report titled "Europe Biosimilar Market Report by Molecule (Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, Adalimumab), Indication (Auto-Immune Diseases, Blood Disorder, Diabetes, Oncology, Growth Deficiency, Female Infertility), Manufacturing Type (In-house Manufacturing, Contract Manufacturing), and Country 2025-2033", the report presents a thorough review featuring the market share, growth, share, trends, and research of the industry.
How Big is the Europe Biosimilar Industry?
The Europe biosimilar market size reached USD 13,864 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 59,733.3 Million by 2033, exhibiting a growth rate (CAGR) of 17.1% during 2025-2033.
For an in-depth analysis, you can refer free sample copy of the report: https://www.imarcgroup.com/europe-biosimilar-market/requestsample
Europe Biosimilar Market Trends:
The market in Europe is above all propelled by the growing demand for a low-cost application, most of all for patients suffering from a chronic condition. Consistent with this, the expanding popularity of biologic drugs close to patent expiry is making biologic drugs more accessible through the biosimilar pipeline, which in turn is contributing to market expansion. In addition, the evolving healthcare network across the region facilitates the broader use of biosimilars with favorable regulatory environments. Additionally, increasing healthcare costs in Europe are allowing patients and providers to actively view biosimilars as a viable option.
Furthermore, the growing pressure to reduce the overall expense of healthcare is driving use of biosimilars and thereby pushing sales of the market. In addition, the increasing endorsement of biosimilar development by governments and health organizations is now acting as a key stimulant of growth. In addition, increasing awareness targeted campaigns promoting the safety and efficacy of biosimilars are promoting their validation among physicians and patients. The growing investments of pharmaceutical companies into biosimilar R&D are also driving the market and offering opportunities for innovation and competition.
Europe Biosimilar Market Scope and Growth Analysis:
The market scope is expanding significantly due to increasing therapeutic applications in areas such as oncology, immunology, and endocrinology, which are addressing unmet clinical needs. In addition, the increasing adoption of biosimilars in hospitals is making it easier for them to be incorporated into mainstream treatment protocols, thus further strengthening the market's position. Furthermore, the inflationary availability of affordable biosimilar drugs is making advanced therapies accessible equitably, especially in emerging economies within Europe.
In addition, strong cooperation between regulatory agencies and pharmaceutical firms is driving the effective approval process, leading to quicker product launches. Local manufacturers are increasing their market share by offering products based on regional demand and preference. Also, adoption of state-of-the-art manufacturing technologies has increased the efficiency of production, decreased costs, and improved supply chain dynamics. Apart from this, the increased focus on interchangeability of biosimilars is building confidence among the prescribers, hence supporting the market's acceptance. According to the market analysis, changes in the reimbursement policies to support biosimilar adoption are impacting the outlook of the market by creating a more favorable environment for industry players and healthcare systems.
By the IMARC Group, the Top Competitive Landscapes Operating in the Industry:
Europe Biosimilar Market Segmentation:
The market report offers a comprehensive analysis of the segments, highlighting those with the largest Europe biosimilar market share. It includes forecasts for the period 2025-2033 and historical data from 2019-2024 for the following segments.
Breakup by Molecule:
Breakup by Indication:
Breakup by Manufacturing Type:
Breakup by Country:
Key highlights of the Report:
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.
IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
We do not claim ownership of any content, links or images featured on this post unless explicitly stated. If you believe any content or images infringes on your copyright, please contact us immediately for removal ([email protected]). Please note that content published under our account may be sponsored or contributed by guest authors. We assume no responsibility for the accuracy or originality of such content. We hold no responsibilty of content and images published as ours is a publishers platform. Mail us for any query and we will remove that content/image immediately.
Copyright © 2024 IndiBlogHub.com. Hosted on Digital Ocean
